Skip to main content
. 2017 May 10;9(6):137–154. doi: 10.1177/1756287217702797

Figure 3.

Figure 3.

Change from baseline to EoT in PVR volume (pooled 12-week studies only) (SAF): (a) males with a history of LUTS associated with BPH/BPE, and (b) males without a history of LUTS associated with BPH/BPE.

BPE, benign prostatic enlargement; BPH, benign prostatic hyperplasia; CI, confidence interval; EoT, end of treatment; LUTS, lower urinary tract symptoms; PVR, post-void residual; SAF, safety analysis set; SD, standard deviation.